Genetic testing of patients was performed after the pharmacological treatment of patients, therefore, they did not affect the selection of the dose of several beta-1 adrenergic receptor antagonists used in the treatment of cardiac arrhythmias. Here, ADRB1 is linked to chronic obstructive pulmonary disease.